Skip to main content
Fig. 7 | Respiratory Research

Fig. 7

From: Safety and immunogenicity of three doses of non-typeable Haemophilus influenzae-Moraxella catarrhalis (NTHi-Mcat) vaccine when administered according to two different schedules: a phase 2, randomised, observer-blind study

Fig. 7

Frequency of non-typeable Haemophilus influenzae antigen (PD, PE, PilA) and Moraxella catarrhalis antigen (UspA2) specific CD4+ T cells expressing at least two markers among CD40 ligand (CD40L), interleukin (IL)-2, tumour necrosis factor (TNF)-α, interferon (IFN)-ɣ, IL-13 and IL-17 (cell-mediated immune response analysis subset). Median, first/third quartile (Q1/Q3) and maximum/minimum (Max/Min) percentages shown. PD, protein D; PE, protein E; PilA, Pilin A; UspA2, ubiquitous surface protein A2. 0–2–6 schedule, group given vaccine at 0–2–6 months and placebo at 12 months; 0–2–12 schedule, group given vaccine at 0–2–12 months and placebo at 6 months. Number of participants with available results at each time point: between 17 and 21 in 0–2–6 group, 17 or 19 in 0–2–12 group

Back to article page

Respiratory Research

ISSN: 1465-993X

Contact us